SLGL
SLGL
NASDAQ · Pharmaceuticals

Sol-Gel Technologies Ltd

$63.81
-1.88 (-2.86%)
As of Nov 7, 2:20 AM ET ·
Financial Highlights (FY 2026)
Revenue
21.78M
Net Income
-6,883,417
Gross Margin
—
Profit Margin
-31.6%
Rev Growth
+71.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 29.4% 29.4%
Operating Margin -38.9% -35.0% 42.3% 41.5%
Profit Margin -31.6% -30.0% 33.8% 28.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 21.78M 12.74M 80.43M 74.82M
Gross Profit — — 23.62M 21.97M
Operating Income -8,468,718 -4,458,262 34.02M 31.02M
Net Income -6,883,417 -3,623,698 27.17M 21.09M
Gross Margin — — 29.4% 29.4%
Operating Margin -38.9% -35.0% 42.3% 41.5%
Profit Margin -31.6% -30.0% 33.8% 28.2%
Rev Growth +71.0% +71.0% -4.6% -5.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 45.73M 50.34M
Total Equity — — 128.24M 118.27M
D/E Ratio — — 0.36 0.43
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -8,346,296 -4,637,916 38.14M 36.98M
Free Cash Flow — — 15.33M 13.15M